IL295236A - Methods of treating and preventing engraftment arrhythmias - Google Patents

Methods of treating and preventing engraftment arrhythmias

Info

Publication number
IL295236A
IL295236A IL295236A IL29523622A IL295236A IL 295236 A IL295236 A IL 295236A IL 295236 A IL295236 A IL 295236A IL 29523622 A IL29523622 A IL 29523622A IL 295236 A IL295236 A IL 295236A
Authority
IL
Israel
Prior art keywords
administration
amiodarone
ivabradine
cardiomyocytes
subject
Prior art date
Application number
IL295236A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Washington
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Univ Vanderbilt filed Critical Univ Washington
Publication of IL295236A publication Critical patent/IL295236A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL295236A 2020-02-10 2021-02-09 Methods of treating and preventing engraftment arrhythmias IL295236A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972330P 2020-02-10 2020-02-10
PCT/US2021/017220 WO2021163037A1 (en) 2020-02-10 2021-02-09 Methods of treating and preventing engraftment arrhythmias

Publications (1)

Publication Number Publication Date
IL295236A true IL295236A (en) 2022-10-01

Family

ID=77291628

Family Applications (1)

Application Number Title Priority Date Filing Date
IL295236A IL295236A (en) 2020-02-10 2021-02-09 Methods of treating and preventing engraftment arrhythmias

Country Status (11)

Country Link
US (1) US20230077983A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103206A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023512843A (cg-RX-API-DMAC7.html)
KR (1) KR20220140532A (cg-RX-API-DMAC7.html)
CN (1) CN115484966A (cg-RX-API-DMAC7.html)
AU (1) AU2021218653A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015768A2 (cg-RX-API-DMAC7.html)
CA (1) CA3166678A1 (cg-RX-API-DMAC7.html)
IL (1) IL295236A (cg-RX-API-DMAC7.html)
MX (1) MX2022009807A (cg-RX-API-DMAC7.html)
WO (1) WO2021163037A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3979997A1 (en) * 2019-06-06 2022-04-13 Novo Nordisk A/S Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof
US20230250393A1 (en) * 2022-02-09 2023-08-10 University Of Washington Pre-treating cardiomyocytes with anti-arrhythmic drugs to reduce engraftment arrhythmia
WO2023173123A1 (en) * 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
JP2025532951A (ja) * 2022-09-28 2025-10-03 ブルーロック・セラピューティクス・リミテッド・パートナーシップ 移植関連不整脈を処置するための組成物および方法
AU2024406171A1 (en) * 2023-12-22 2026-06-18 Bluerock Therapeutics Lp Molecular identification of cardiomyocytes for cardiac cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192305A1 (en) * 2012-01-20 2013-08-30 Singapore Health Serv Pte Ltd Induced pluripotent stem cell (ipsc)-derived cardiomyocyte-like cells and uses thereof in screening for agents
EP2833930B1 (en) * 2012-04-04 2018-05-30 University of Washington through its Center for Commercialization Systems and method for engineering muscle tissue
EP3288626B8 (en) * 2015-04-27 2025-12-10 Tulavi Therapeutics, Inc. Substances and compositions for use in blocking nerve regeneration
US11752176B2 (en) * 2017-03-15 2023-09-12 University Of Washington Methods and compositions for enhancing cardiomyocyte maturation and engraftment
EP3979997A1 (en) * 2019-06-06 2022-04-13 Novo Nordisk A/S Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof

Also Published As

Publication number Publication date
AU2021218653A1 (en) 2022-09-01
JP2023512843A (ja) 2023-03-29
CA3166678A1 (en) 2021-08-19
BR112022015768A2 (pt) 2022-11-22
KR20220140532A (ko) 2022-10-18
WO2021163037A1 (en) 2021-08-19
EP4103206A1 (en) 2022-12-21
CN115484966A (zh) 2022-12-16
EP4103206A4 (en) 2024-03-13
MX2022009807A (es) 2022-11-10
US20230077983A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
US20230077983A1 (en) Methods of treating and preventing engraftment arrhythmias
Biressi et al. Stem cell therapy for muscular dystrophies
Manole et al. Experimental acute myocardial infarction: telocytes involvement in neo‐angiogenesis
Dubois et al. Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction
EP3556378A1 (en) Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
JP7091427B2 (ja) 心不全の治療方法
IL223453A (en) Use of 1-tgfb, 4bmp, a- thrombin cardiotropin and cardiogenol c in the treatment of ischemic cardiac therapy, myocardial infarction, or heart failure
Dong et al. Therapeutic mitochondrial transfer via mesenchymal stem cell-derived microvesicles for macrophage modulation in myocardial infarction complicated by diabetes
WO2018026766A1 (en) Compositions and methods for treating cardiac injury
WO2012030919A2 (en) Composition and method for muscle repair and regeneration
Li et al. Enhanced human adipose‐derived stem cells with VEGFA and bFGF mRNA promote stable vascular regeneration and improve cardiac function following myocardial infarction
US20120020925A1 (en) Therapeutic Use of Specialized Endothelial Progenitor Cells
US8889122B2 (en) Cellular cardiomyoplasty as supportive therapy in patients with heart disease
JP2024514215A (ja) 間葉系幹細胞および血管内皮前駆細胞を有効性分として含む、閉鎖性血管疾患またはその合併症予防または治療用組成物
US20230250393A1 (en) Pre-treating cardiomyocytes with anti-arrhythmic drugs to reduce engraftment arrhythmia
Borenstein et al. Non-cultured cell transplantation in an ovine model of non-ischemic heart failure
Ovokaitys et al. Intravenous SONG-modulated laser-activated allogeneic cord blood mesenchymal stem cells for the treatment of endstage heart failure: a preliminary clinical study
Zhang et al. Management of Engraftment Arrhythmias Associated with Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Transplantation
Molino Beta-3 Adrenoceptor (β3-AR) agonism is a promising strategy against bronchopulmonary dysplasia
Rodrigo Intramyocardial bone marrow cell injection for ischemic heart disease: efficacy
Ramshorst Intramyocardial bone marrow cell injection: clinical and functional effects in ischemic heart disease
Taylor et al. Cell transplantation for cardiovascular repair
Murrow et al. Cell therapy for cardiovascular disease
Sherman et al. Burning questions in heart failure management: why do surgeons and interventional cardiologists talk of regenerative cell therapy?
Qayyum et al. Clinical Study Adipose-Derived Stromal Cells for Treatment of Patients with Chronic Ischemic Heart Disease (MyStromalCell Trial): A Randomized Placebo-Controlled Study